Your search for major depressive disorder returned 154 results

Can pain intensity scores predict psychosocial outcomes longitudinally? This study examines that question.

While statins have both good and bad outcomes in the realm of neuropsychiatry, researchers looked at the possible associations with statins and suicidality, depression, anxiety, and seizures.

In patients with dementia, pain is a correlate or prodromal symptom rather than a direct cause of dementia.

Investigating whether serial ketamine treatments change functional connectivity between limbic structures and resting-state networks.

Exploring the risk of alcohol use disorders in patients with insomnia.

Proinflammatory cytokines, tryptophan catabolites, and the gut-brain axis may have key roles in chronic fatigue and depression in patients with multiple sclerosis.

The comorbidity of depressive disorders and late-life neurodegenerative diseases including Alzheimer disease has been widely reported. This study looks into whether there is a causal relationship existing between both or, if their co-occurrence is due to confounding or common risk factors, such as aging.

Examining the potential shared genetic liability of sleep deficits and cannabis use behaviors using multiple genomic methods.

Adults with chronic subjective tinnitus who receive treatment with a device that combines sound and tongue stimulation may experience a significant reduction in tinnitus symptom severity.

Researchers performed a double-blind randomized study to investigate the efficacy of tDCS as an augmentation strategy to sertraline in the treatment of vascular depression.

This study highlights the importance of transdiagnostic approaches to psychiatry.

Serotonergic antidepressants are effective for sleep disturbances in perimenopausal and postmenopausal women even without major depressive disorder.

Patients received 40 Hz gamma tACS to provide data on the use of varying stimulation periods.

Analysis of the HARMONY trial was conducted to evaluate the prevention of relapse in patients with dementia-related psychosis who have been treated with pimavanserin.

A pooled analysis evaluated reductions in migraine and headache days among patients with chronic migraine and comorbid depression in 2 placebo-controlled, phase 3 trials of fremanezumab.

SSRI use after intracerebral hemorrhage may resolve depression symptoms, but also increases patients’ risk for recurrent stroke.

Researchers conducted a study to evaluate the validity of, and satisfaction with, the Cognition KIT DSST mobile app in patients with major depressive disorder.

Is there a causal relationship between depressive disorders and late-life neurodegenerative diseases? Or, is their co-occurrence due to confounding or common risk factors, such as aging?

Testing for genetic variants may allow clinicians to predict how patients with major depressive disorder metabolize antidepressants.

Researchers conducted an 8-week, open-label, single-arm study and a subsequent 2-stage, sequential, parallel comparison study to assess the use of pimavanserin among patients with Parkinson disease and major depressive disorder.

In early Parkinson Disease, fatigue, excessive daytime sleepiness, and emotional apathy are predictive of increasing fatigue severity.

Most older adults with preexisting MDD showed resilience in the first two months of the COVID-19 pandemic, but they express concerns about the future.

There is no evidence supporting the causal role of disturbed sleep patterns on AD or between major depression and AD.

Higher levels of outdoor artificial light at night are associated with less favorable sleep patterns as well as mood and anxiety disorders in adolescents.

Study findings do not support the use of vitamin D3 supplementation to prevent depression in adults.

Children, adolescents, and young adults have greater risk of self-injurious behavior and suicide ideation if they have a childhood history of epilepsy.

The use of genetic evaluation for suicidal ideation may represent a future application for precision medicine.

Authors of a paper share their perspectives on the topic of chronic pain in individuals with mental health disorders.

The approval was based on the ASPIRE I and II trials that compared the efficacy and safety of esketamine, an N-methyl-D-aspartate receptor antagonist, to placebo in 449 adults with moderate to severe MDD who had active suicidal ideation and intent.

The applications are supported by positive results from a double-masked, 4-week, pivotal phase 2/3 clinical trial that compared the effects of tasimelteon to placebo in 25 patients with SMS.